Vol. 5 (03) pp. 844-852 DOI: 10.21474/IJAR01/3580

UPDATE ON THE BIOMARKERS FOR TARGETED THERAPY IN TRIPLE-NEGATIVE BREAST CANCER.

and
  • Department of surgical oncology, Faculty of Medicine, University of Tabuk, Kingdom of Saudi Arabia.
  • Inderprastha Dental College & Hospital , Industrial Area, Sahibabad ,Ghaziabad, U.P- 201 010 India.
20 Downloads 147 Views
Crossref

Download Full Paper (PDF)

Abstract

Breast cancers that demonstrate the absence of estrogen receptor and progesterone receptor and no overexpression of human epidermal growth factor receptor 2 (HER2) are referred to as triple-negative breast cancer (TNBC). Globally 1 million cases of breast cancer are diagnosed annually and Triple-negative breast cancer comprises 15%-20% of all breast cancers. The last decade has seen a revolution in the understanding of breast cancer, with new classifications proposed that have significant prognostic value and provide guides to treatment options. There are many biomarkers in TNBC used for its sub-classification. Clinically-practical assay/biomarkers that can reliably identify TNBC are necessary. Biomarkers may be useful as prognostic or predictive indicators as well as suggest possible targets for novel therapies.

Article Analytics

References

  1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012.?CA Cancer J Clin. 2015;65(2):87?108
  2. Perou CM, S?rlie T, Eisen MB, et al. Molecular portraits of human breast tumours.?Nature. 2000;406(6797):747?752
  3. Boyle .Triple-negative breast cancer: epidemiological considerations and recommendations . Ann Oncol (2012) 23 (suppl_6): vi7-vi12
  4. S?rlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.?Proc NatlAcadSci U S A. 2001;98(19):10869?108-74
  5. Brenton JD, Carey LA, Ahmed AA, Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application?J ClinOncol.?2005;23:7350?60.
  6. Reis?Filho JS, Westbury C, Pierga JY. The impact of expression profiling on prognostic and predictive testing in breast cancer.J ClinPathol.?2006;59:225?31.
  7. Calza S, Hall P, Auer G, et al. Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients.?Breast Cancer Res.?2006;8:R34.
  8. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.?JAMA.?2006;295:2492?502.
  9. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.J Clin Invest.?2011;121:2750?2767
  10. Siziopikou KP, Cobleigh M. The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies.?2007;16:104?107
  11. Bhargava R, Gerald WL, Li AR, Pan Q, Lal P, Ladanyi M, Chen B. EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations.Mod Pathol.?2005;18:1027?1033.
  12. Bidard FC, Conforti R, Boulet T, Michiels S, Delaloge S, Andr? F. Does triple-negative phenotype accurately identify basal-like tumour? An immunohistochemical analysis based on 143 ?triple-negative? breast cancers.Ann Oncol.?2007;18:1285?1286.
  13. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer.?2007;109:25?32.
  14. Nogi H, Kobayashi T, Suzuki M, Tabei I, Kawase K, Toriumi Y, Fukushima H, Uchida K. EGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancer.Oncol Rep.?2009;21:413?417.
  15. Mehdizadeh R, Nazafi S, Jahanjad I. Evaluation of EGFR, VEGFR2, IGF-1R, and HIF-1a expression and their prognostic value in Iranian triple negative breast cancer patients.?2012;48:S145.
  16. Achen MG, Stacker SA. The vascular endothelial growth factor family; proteins which guide the development of the vasculature.Int J Exp Pathol.?1998;79:255?265
  17. Ferrara N. Role of vascular endothelial growth factor in the regulation of angiogenesis.Kidney Int.?1999;56:794?814.
  18. Benjamin LE, Keshet E. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal.Proc NatlAcadSci USA.?1997;94:8761?8766.
  19. Linderholm BK, Hellborg H, Johansson U, Elmberger G, Skoog L, Lehti? J, Lewensohn R. Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer.Ann Oncol.?2009;20:1639?1646
  20. Ryd?n L,?Jirstr?m K,?Haglund M,?St?l O,?Fern?.Epidermal?growth?factor?receptor and? vascular ?endothelial ?growth?factor?receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up.Breast Cancer Res Treat.2010 Apr;120(2):491-8
  21. Qiu WG, Polotskaia A, Xiao G, Di L, Zhao Y, Hu W, Philip J, Hendrickson RC, BargonettiJ.NPJ.Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative?breast cancer.Breast Cancer. 2017;3.
  22. Qiao W, Pan L, Kou C, Li K, Yang M.Prognostic and clinicopathological value of?poly?(adenosine diphosphate-ribose)?polymerase?expression in?breast cancer: A meta-analysis.PLoS One. 2017 Feb 17;12(2):e0172413
  23. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O?Connor MJ, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.N Engl J Med.?2009;361:123?134
  24. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.?2005;434:913?917
  25. Evers B, Drost R, Schut E, de Bruin M, van der Burg E, Derksen PW, Holstege H, Liu X, van Drunen E, Beverloo HB, et al. Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin.Clin Cancer Res.?2008;14:3916?3925
  26. Bhattacharyya A, Ear US, Koller BH, Weichselbaum RR, Bishop DK. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin.J Biol Chem.?2000;275:23899?23903
  27. Hastak K, Alli E, Ford JM. Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin.Cancer Res.?2010;70:7970?7980
  28. .Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.??2005;434:917?921.
  29. Mackiewicz M, Huppi K, Pitt JJ, Dorsey TH, Ambs S and Caplen NJ: Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA. Breast Cancer Res Treat. 130:663?679. 2011
  30. Janssen EA, Slewa A, Gudlaugsson E, et al: Biologic profiling of lymph node negative breast cancers by means of microRNA expression. Mod Pathol. 23:1567?1576. 2010
  31. Farazi TA, Ten Hoeve JJ, Brown M, et al: Identification of distinct miRNA target regulation between breast cancer molecular subtypes using AGO2-PAR-CLIP and patient datasets. Genome Biol. 15:R92014
  32. Dong G, Liang X, Wang D, et al: High expression of miR-21 in triple-negative breast cancers was correlated with a poor prognosis and promoted tumor cell in vitro proliferation. Med Oncol. 31:572014
  33. Wang C, Zheng X, Shen C and Shi Y: MicroRNA-203 suppresses cell proliferation and migration by targeting BIRC5 and LASP1 in human triple-negative breast cancer cells. J Exp Clin Cancer Res. 31:582012
  34. Buffa FM, Camps C, Winchester L, et al: microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. Cancer Res. 71:5635?5645. 2011
  35. Toyama T, Kondo N, Endo Y, et al: High expression of microRNA-210 is an independent factor indicating a poor prognosis in Japanese triple-negative breast cancer patients. Jpn J ClinOncol. 42:256?263. 2012.
  36. Kong W, He L, Richards EJ, et al: Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer. Oncogene. 33:679?689. 2014
  37. Shen S, Sun Q, Liang Z, et al: A prognostic model of triple-negative breast cancer based on miR-27b-3p and node status. PLoS One. 9:e1006642014.
  38. Svoboda M, Sana J, Redova M, et al: MiR-34b is associated with clinical outcome in triple-negative breast cancer patients. DiagnPathol. 7:312012
  39. Avery-Kiejda KA, Braye SG, Mathe A, Forbes JF and Scott RJ: Decreased expression of key tumour suppressor microRNAs is associated with lymph node metastases in triple negative breast cancer. BMC Cancer. 14:512014
  40. Radojicic J, Zaravinos A, Vrekoussis T, Kafousi M, Spandidos DA and Stathopoulos EN: MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer. Cell Cycle. 10:507?517. 2011
  41. Andre F, Job B, Dessen P, Tordai A, Michiels S, Liedtke C, Richon C, Yan K, Wang B, Vassal G, et al. Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array.Clin Cancer Res.?2009;15:441?451.
  42. Edling CE, Hallberg B. c-Kit--a hematopoietic cell essential receptor tyrosine kinase.Int J Biochem Cell Biol.?2007;39:1995?1998.
  43. Schweizer J, Bowden PE, Coulombe PA, Langbein L, Lane EB, Magin TM, Maltais L, Omary MB, Parry DA, Rogers MA, et al. New consensus nomenclature for mammalian keratins.J Cell Biol.?2006;174:169?174.
  44. Otterbach F, B?nkfalvi A, Bergner S, Decker T, Krech R, Boecker W. Cytokeratin 5/6 immunohistochemistry assists the differential diagnosis of atypical proliferations of the breast.?2000;37:232?240.
  45. Abd El-Rehim DM, Pinder SE, Paish CE, Bell J, Blamey RW, Robertson JF, Nicholson RI, Ellis IO. Expression of luminal and basal cytokeratins in human breast carcinoma.J Pathol.?2004;203:661?671
  46. Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki67 in early breast cancer.?J ClinOncol.?2005;23:7212?7220.
  47. Zhou CJ, Zhang QH, Zhang TG, Sun SZ, Li H, Wang Y, Liu ZY. Expression of ER, Ki67 and cylinD1 in the pre-cancerous breast of Chinese patients.?PatholOncol Res.?2009;15:153?158.
  48. Harvey JA, Santen RJ, Petroni GR, Bovbjerg VE, Smolkin ME, Sheriff FS, Russo J. Histologic changes in the breast with menopausal hormone therapy use: correlation with breast density, estrogen receptor, progesterone receptor, and proliferation indices.??2008;15:67?73.
  49. Fasching PA, Heusinger K, Haeberle L, Niklos M, Hein A, Bayer CM, Rauh C, Schulz-Wendtland R, Bani MR, Schrauder M, et al. Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment.?BMC Cancer.?2011;11:486.
  50. Tanei T, Shimomura A, Shimazu K, Nakayama T, Kim SJ, Iwamoto T, Tamaki Y, Noguchi S. Prognostic significance of Ki67 index after neoadjuvant chemotherapy in breast cancer.?Eur J SurgOncol.?2011;37:155?161.
  51. Selz J, Stevens D, Jouanneau L, Labib A, Le Scodan R. Prognostic value of molecular subtypes, ki67 expression and impact of postmastectomy radiation therapy in breast cancer patients with negative lymph nodes after mastectomy.?Int J RadiatOncolBiol Phys.?2012;84:1123?1132.
  52. Keam B, Im SA, Lee KH, Han SW, Oh DY, Kim JH, Lee SH, Han W, Kim DW, Kim TY, et al. Ki67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis.?Breast Cancer Res.?2011;13:R22
  53. Ito F,?Furukawa N,?NakaiT.Evaluation of TOP2A as a Predictive Marker for Endometrial Cancer With Taxane-Containing Adjuvant Chemotherapy.Int J Gynecol Cancer.2016 Feb;26(2):325-30.
  54. Nikol?nyi A1,?S?k?sd F,?Kaizer L,?Cs?rgo E,?V?r?s A,?Uhercs?k G,?Orm?ndi K,?L?z?r G,?Thurz? L,?Brodowicz T,?Kah?nZ.Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.2011;80(3-4):269-77.
  55. Watt PM, Hickson ID (1994)."Structure and function of type II DNA topoisomerases.".? J.?303?(3): 681?95
  56. Burgess DJ, Doles J, Zender L, Xue W, Ma B, McCombie WR, Hannon GJ, Lowe SW, Hemann MT. Topoisomerase levels determine chemotherapy response in vitro and in vivo.?Proc NatlAcadSci USA.?2008;105:9053?9058.
  57. Knoop AS, Knudsen H, Balslev E, Rasmussen BB, Overgaard J, Nielsen KV, Schonau A, Gunnarsd?ttir K, Olsen KE, Mouridsen H, et al. retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group.J ClinOncol.?2005;23:7483?7490.
  58. Weigelt B, Horlings HM, Kreike B, Hayes MM, Hauptmann M, Wessels LF, de Jong D, Van de Vijver MJ, Van?t Veer LJ, Peterse JL. Refinement of breast cancer classification by molecular characterization of histological special types.J Pathol.?2008;216:141?150
  59. Bradham C, McClay DR. (2006). p38 MAPK in development and cancer.?Cell Cycle5: 824?828.
  60. Brancho D, Tanaka N, Jaeschke A, Ventura JJ, Kelkar N, Tanaka Y?et al. (2003). Mechanism of p38 MAP kinase activation?in vivo.?Genes Dev17: 1969?1978.
  61. Jing J, Greshock J, Holbrook JD, Gilmartin A, Zhang X, McNeil E, Conway T, Moy C, Laquerre S, Bachman K, Wooster R, DegenhardtY.Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212.Mol Cancer Ther. 2012 Mar; 11(3):720-9.
  62. Grob TJ, Heilenk?tter U, Geist S, Paluchowski P, Wilke C, Jaenicke F, Quaas A, Wilczak W, Choschzick M, Sauter G, LebeauA.Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer.Breast Cancer Res Treat. 2012 Jul; 134(2):561-7.

How to Cite This Article

Ibrahim Abdullah Al Balawi and Tahir Ahmad Mir. (2017); UPDATE ON THE BIOMARKERS FOR TARGETED THERAPY IN TRIPLE-NEGATIVE BREAST CANCER., Int. J. of Adv. Res., 5 (03), 844-852, ISSN 2320-5407. DOI: https://doi.org/10.21474/IJAR01/3580

Corresponding Author

Dr. Ibrahim Abdullah Albalawi
1Department of surgical oncology , Faculty of Medicine, University of Tabuk, Kingdom of Saudi Arabia.
Creative Commons Attribution 4.0 This work is licensed under a Creative Commons Attribution 4.0 International License.